Frontlight ResearchEarly access
WithdrawnPhase 2
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
Key facts
- Who runs it
- Valo Health, Inc.
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Sept 2022
- Ended
- Nov 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- OPL-0301 Dose 1
- OPL-0301 Dose 2
- Placebo
- Record updated
- 21 February 2023
- Why it stopped
- Withdrawn based on business decision, no participants enrolled
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Are male or female between 18 and 90 years of age, inclusive, at the time of signing the informed consent
- Are hospitalized with acute ST-Elevated Myocardial Infarction (STEMI), defined based on American Heart Association (AHA)/American College of Cardiology (ACC) criteria
- Have cardiac troponin-I (cTnI), cardiac troponin-T (cTnT) levels ≥10x upper limit of normal (ULN) at least once during the index event of myocardial infarction
Who cannot take part
- Previous history of documented myocardial infarction
- Previous history of percutaneous coronary intervention (PCI) within 6 months or coronary artery bypass graft surgery (CABG) or valvular heart surgery at any time prior to screening
- Previous history of decompensated heart failure
- Previous history of documented specific cardiomyopathy (including but not limited to hypertrophic cardiomyopathy (HCM), amyloid, sarcoid, etc.)
- Previous history of documented arrhythmias
- Are being treated with Sphingosine-1 Phosphate (S1P) modulators (fingolimod, siponimod, ozanimod, ponesimod)
- Previous history of documented chronic left ventricular dysfunction with ejection fraction (EF) < 50%
About the trial
What the trial wants to find out
Study OPL-0301-201 is intended to generate efficacy and safety data of OPL-0301 in participants with post-myocardial infarction (MI) left ventricular dysfunction (LVD)
The 3 groups in the trial
- OPL-0301 Dose 1Treatment being tested
Participants are randomized to OPL-0301 Dose 1 administered once daily for 90 days
- OPL-0301 Dose 2Treatment being tested
Participants are randomized to OPL-0301 Dose 2 administered once daily for 90 days
- PlaceboPlacebo, for comparison
Participants are randomized to matching placebo administered once daily for 90 days
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-arm, Parallel-group, Adaptive Study to Investigate the Efficacy and Safety of OPL-0301 in Patients With Post-myocardial Infarction Left Ventricular Dysfunction (RESTORE)
- Record updated
- 21 February 2023